Nanomedical Diagnostics Releases Report on Field Effect Biosensing (FEB) Versus Isothermal Titration Calorimetry (ITC)

News provided by

Nanomedical Diagnostics, Inc.

Jun 05, 2018, 03:00 ET


SAN DIEGO (PRWEB) June 05, 2018 -- Nanomedical Diagnostics, leading manufacturer of graphene biosensors that accelerate pharmaceutical and biotherapeutics development, released a report for biochemists and chemists entitled, “Field Effect Biosensing versus Isothermal Titration Calorimetry Binding Measurements of Rho GTPase,” comparing the amount of material and time used to gather interaction data using both techniques.

As a label-free method to gain binding affinity data, ITC is commonly employed for secondary screening during drug discovery. However, high protein consumption and low throughput severely limit the number of compounds that can be characterized using this technique. This report presents a novel electrical methodology called Field Effect Biosensing (FEB) that uses substantially less material and time to deliver direct binding measurements, providing biochemists a compelling orthogonal option to confirm primary hits.

“In this Rho GTPase and GAP binding experiment, we found that the amount of protein used with Agile R100, our FEB instrument, was just 4% of what ITC required,” says Nanomedical Diagnostics CEO, Ross Bundy. “With Agile R100, we ran the measurement experiment in just 4 hours compared to the ITC instrument’s 16 hours, and the binding affinity data attained was consistent. This makes Agile R100 a viable quick-check tool to verify hits identified in primary screening.”

In addition to binding affinity, FEB provides kinetic values such as on-rates and off-rates that are unattainable through ITC. These rate constants let researchers discover more about a drug’s potential residence time, toxicity, and selectivity.

This report covers:

  • Experimental parameters in gathering binding data of Rho GTPase interacting with GAP using Agile R100, an FEB instrument, and MicroCal iTC200, an ITC platform.
  • Affinity values are shown to be consistent through both techniques.
  • Additional kinetic rate constants (on-rates and off-rates) are provided by Agile R100.

View this complimentary report at http://www.nanomedicaldiagnostics.com/agiler100-vs-itc-pdf

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a life science company based in San Diego, CA. Nanomed has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers sensitive label-free kinetic characterization of biomolecular interactions for accelerated drug discovery. As the world’s leading developer and manufacturer of next-generation graphene biosensors, Nanomed’s mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and portable diagnostic and health monitoring platforms.

Angela Shue, Nanomedical Diagnostics, Inc., http://www.nanomedicaldiagnostics.com, +1 (858) 255-4330, [email protected]